Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting



Status:Recruiting
Conditions:Blood Cancer, Hematology, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/30/2019
Start Date:May 29, 2014
End Date:December 31, 2024
Contact:Associate Director Clinical Trial Disclosure
Email:clinicaltrialdisclosure@celgene.com
Phone:1-888-260-1599

Use our guide to learn which trials are right for you!

A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting.

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and
low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) ,
daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed
or refractory multiple myeloma who have received a first or second line treatment of
lenalidomide-based therapy.

This trial will test the hypothesis for Cohort A that the proportion of patients will have an
Overall Response Rate (ORR) of > 30 % to reveal that Pomalidomide is efficacious in
pretreated patients who are refractory to lenalidomide.

This trial will test the hypothesis for Cohort B that the proportion of patients will have an
Overall Response Rate (ORR) of > 70 % to reveal that POM+DARA+LD-Dex is efficacious in
pretreated patients who are refractory to lenalidomide.

A phase 2, multicenter, multi-cohort, open-label study of pomalidomide in combination with
low-dose dexamethasone or pomalidomide in combination with low-dose dexamethasone and
daratumumab in subjects with relapsed or refractory multiple myeloma following lenalidomide
based therapy in the first or second line setting.

This trial will assess, Overall Response Rate (ORR), Overall Survival (OS), Progression-Free
Survival (PFS), Duration of Response (DoR), Time to Response (TTR), Time to Progression(TTP)
and safety.

Inclusion Criteria:

- Subjects must satisfy the following criteria to be enrolled in the study:

1. Adults (age ≥ 18 years at the time of signing the ICD) with documented diagnosis of MM
and measurable disease (serum M-protein ≥ 0.5 g/dL or urine M-protein ≥ 200 mg/24
hours).

2. Subjects enrolling in Cohort A (Pom+LD-dex) must have received 2 prior treatment lines
of anti-myeloma therapy. Subjects enrolling in Cohort B (Pom+Dara+LD-dex) must have
received 1 or 2 prior treatment lines of anti-myeloma therapy.

3. All subjects must have received prior treatment with LEN or a LEN-containing regimen
for at least 2 consecutive cycles as the most recent treatment regimen.

4. All subjects must have documented disease progression during or after their last
antimyeloma therapy.

5. Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status
score of 0, 1, or 2.

6. Subjects must understand and voluntarily sign an ICD prior to any study related
assessments/procedures being conducted.

7. Subjects must be able to adhere to the study visit schedule and other protocol
requirements.

8. All subjects must provide an adequate bone marrow sample at screening that
definitively evaluates the presence or absence of myelodysplastic changes.

9. Females with child-bearing potential (FCBP†) must agree to use 2 reliable forms of
contraception* simultaneously or practice complete abstinence from heterosexual
contact for at least 28 days before starting study drug, while participating in the
study (including during dose interruptions), and for at least 28 days after study
treatment discontinuation and must agree to regular pregnancy testing during this
timeframe. For subjects enrolled in Cohort B, pregnancy prevention and testing will
continue until 3 months after last dose of daratumumab.

10. Females must agree to abstain from breastfeeding during study participation and 28
days after study drug discontinuation. Female subjects enrolled in Cohort B must agree
to abstain from breastfeeding and donating eggs during study participation and until 3
months after last dose of daratumumab.

11. Males must agree to use a latex condom during any sexual contact with FCBP while
participating in the study and for 28 days following discontinuation from this study,
even if he has undergone a successful vasectomy. Male subjects enrolled in Cohort B
must agree to use a latex condom during any sexual contact with FCBP while
participating in the study and until 3 months after last dose of daratumumab.

12. Males must also agree to refrain from donating semen or sperm during the treatment
phase and for 28 days after discontinuation from this study treatment. Male subjects
enrolled in Cohort B must also agree to refrain from donating semen or sperm during
the treatment phase and until 3 months after last dose of daratumumab.

13. All subjects must agree to refrain from donating blood while on study therapy and for
28 days after discontinuation from this study treatment.

14. All subjects must agree not to share medication.

Exclusion Criteria:

The presence of any of the following will exclude a subject from study enrollment:

1. Any of the following laboratory abnormalities:

- Absolute neutrophil count < 1,000/μL

- Platelet count < 75,000/μL for subjects in whom < 50% of bone marrow nucleated
cells are plasma cells; or a platelet count < 30,000/μL for subjects in whom ≥
50% of bone marrow nucleated cells are plasma cells.

- Severe renal impairment (Creatinine Clearance [CrCl] < 30 mL/min) requiring
dialysis.

- Corrected serum calcium > 11.5 mg/dL (> 2.8 mmol/L)

- Hemoglobin < 8 g/dL (< 4.9 mmol/L; prior red blood cell transfusion or
recombinant human erythropoietin use is permitted)

- Serum SGOT/AST or SGPT/ALT > 3.0 x the upper limit of normal (ULN)

- Serum total bilirubin > 2.0 mg/dL (34.2 μmol/L); or > 3.0 x ULN for subjects with
hereditary benign hyperbilirubinemia

2. Prior history of malignancies, other than MM, unless the subject has been free of the
disease for ≥ 5 years. Allowed exceptions include the following:

- Basal or squamous cell carcinoma of the skin

- Carcinoma in situ of the cervix or breast

- Incidental histological finding of prostate cancer (TNM [tumor, nodes,
metastasis] stage of T1a or T1b)

3. Previous therapy with pomalidomide or daratumumab

4. Hypersensitivity to thalidomide, LEN, or dex (this includes ≥ Grade 3 rash during
prior thalidomide or LEN therapy)

5. Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem
cell transplant less than 12 months prior to initiation of study treatment and who
have not discontinued immunosuppressive treatment for at least 4 weeks prior to
initiation of study treatment and are currently dependent on such treatment.

6. Subjects with any one of the following:

- Congestive heart failure (NY Heart Association Class III or IV)

- Myocardial infarction within 12 months prior to starting study treatment

- Unstable or poorly controlled angina pectoris, including Prinzmetal's variant
angina pectoris

7. Subjects who received any of the following within 14 days of initiation of study
treatment:

- Major surgery (kyphoplasty is not considered major surgery)

- Use of any anti-myeloma drug therapy

8. Use of any investigational agents within 28 days or 5 half-lives (whichever is longer)
of treatment, unless approved by the sponsor.

9. Incidence of gastrointestinal disease that may significantly alter the absorption of
Pomalidomide.

10. Subjects unable or unwilling to undergo antithrombotic prophylactic treatment

11. Any serious medical condition, laboratory abnormality, or psychiatric illness that
would prevent the subject from signing the ICD

12. Pregnant or breastfeeding females

13. Known human immunodeficiency virus (HIV) positivity; active infectious hepatitis A, B,
or C; or chronic hepatitis B or C

14. For subjects enrolling in Cohort B - Subject has known allergies, hypersensitivity to
mannitol, corticosteroids, monoclonal antibodies or human proteins, or their
excipients (refer to the Daratumumab IB), or known sensitivity to mammalian-derived
products.
We found this trial at
34
sites
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Los Angeles, California 90095
310-825-4321
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Calgary, Alberta T2N 4Z5
?
mi
from
Calgary,
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
1721 East 19th Ave., Suite #200 & #300
Denver, Colorado 80218
720-754-4800
Colorado Blood Cancer Institute When patients come to the Colorado Blood Cancer Institute, the entire...
?
mi
from
Denver, CO
Click here to add this to my saved trials
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials
East Orange, New Jersey 07018
?
mi
from
East Orange, NJ
Click here to add this to my saved trials
Fairway, Kansas 66205
?
mi
from
Fairway, KS
Click here to add this to my saved trials
Glens Falls, New York 12801
?
mi
from
Glens Falls, NY
Click here to add this to my saved trials
Greenbrae, California 94904
?
mi
from
Greenbrae, CA
Click here to add this to my saved trials
22101 Moross Rd
Gross Pointe, Michigan 48236
?
mi
from
Gross Pointe, MI
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
?
mi
from
Hershey, PA
Click here to add this to my saved trials
Jacksonville, Florida 32256
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kansas City, Missouri 64111
?
mi
from
Kansas City, MO
Click here to add this to my saved trials
Louisville, Kentucky 40207
?
mi
from
Louisville, KY
Click here to add this to my saved trials
Lubbock, Texas 79410
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Mayfield Heights, Ohio 44124
?
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
250 25th Ave N, Ste 100
Nashville, Tennessee 37023
615-320-5090
Tennessee Oncology, PLLC Since 1976 Tennessee Oncology has been providing quality cancer care. In 2013,...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Orlando, Florida 32804
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Pembroke Pines, Florida 33028
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Plano, Texas 75093
?
mi
from
Plano, TX
Click here to add this to my saved trials
Pleasant Hill, California 94523
?
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
1201 5th Avenue North
Saint Petersburg, Florida 33705
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Spokane, Washington 99218
?
mi
from
Spokane, WA
Click here to add this to my saved trials
Stamford, Connecticut 06904
?
mi
from
Stamford, CT
Click here to add this to my saved trials
1414 Southwest 8th Avenue
Topeka, Kansas 66606
?
mi
from
Topeka, KS
Click here to add this to my saved trials
Tucson, Arizona 85724
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Westminster, Maryland 21157
?
mi
from
Westminster, MD
Click here to add this to my saved trials
Whittier, California 90603
?
mi
from
Whittier, CA
Click here to add this to my saved trials